River & Mercantile Asset Management LLP Invests $154,000 in Stryker Co. (NYSE:SYK)

River & Mercantile Asset Management LLP acquired a new position in Stryker Co. (NYSE:SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 750 shares of the medical technology company’s stock, valued at approximately $154,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its position in Stryker by 2.1% during the second quarter. Vanguard Group Inc. now owns 26,735,288 shares of the medical technology company’s stock worth $5,496,241,000 after buying an additional 555,327 shares in the last quarter. FMR LLC grew its position in Stryker by 13.4% during the first quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock worth $1,328,951,000 after buying an additional 793,560 shares in the last quarter. Northern Trust Corp grew its position in Stryker by 0.5% during the second quarter. Northern Trust Corp now owns 3,922,830 shares of the medical technology company’s stock worth $806,455,000 after buying an additional 19,248 shares in the last quarter. Nuveen Asset Management LLC grew its position in Stryker by 20,218.6% during the second quarter. Nuveen Asset Management LLC now owns 2,596,110 shares of the medical technology company’s stock worth $533,708,000 after buying an additional 2,583,333 shares in the last quarter. Finally, Morgan Stanley grew its position in Stryker by 3.4% during the second quarter. Morgan Stanley now owns 1,826,762 shares of the medical technology company’s stock worth $375,547,000 after buying an additional 59,305 shares in the last quarter. Institutional investors and hedge funds own 72.95% of the company’s stock.

Shares of SYK opened at $213.81 on Friday. The company has a market capitalization of $78.89 billion, a P/E ratio of 29.25, a PEG ratio of 2.56 and a beta of 0.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.07 and a quick ratio of 1.26. Stryker Co. has a one year low of $144.75 and a one year high of $223.45. The business’s 50 day simple moving average is $216.98 and its 200-day simple moving average is $203.00.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, topping the consensus estimate of $1.93 by $0.05. The business had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.60 billion. Stryker had a return on equity of 25.98% and a net margin of 24.99%. Stryker’s revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.76 EPS. On average, sell-side analysts anticipate that Stryker Co. will post 8.21 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 0.97%. The ex-dividend date is Friday, September 27th. Stryker’s payout ratio is currently 28.45%.

In related news, insider Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $205.88, for a total value of $960,636.08. Following the completion of the transaction, the insider now owns 155,963 shares in the company, valued at approximately $32,109,662.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $214.16, for a total transaction of $578,232.00. Following the completion of the transaction, the chief financial officer now owns 20,633 shares of the company’s stock, valued at approximately $4,418,763.28. The disclosure for this sale can be found here. Insiders sold a total of 51,637 shares of company stock worth $11,240,206 over the last three months. 7.20% of the stock is owned by company insiders.

SYK has been the topic of a number of recent research reports. Cantor Fitzgerald lifted their price objective on Stryker from $190.00 to $230.00 and gave the company a “neutral” rating in a report on Friday, July 26th. Barclays set a $226.00 price objective on Stryker and gave the company a “buy” rating in a report on Friday, July 26th. Wells Fargo & Co lifted their price objective on Stryker from $219.00 to $228.00 and gave the company an “outperform” rating in a report on Tuesday, July 2nd. Raymond James set a $240.00 price objective on Stryker and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a report on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Day Trading

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.